Introduction {#S1}
============

Antibody-mediated rejection remains an important barrier to improving long-term survival after solid organ transplantation ([@B1]--[@B3]). In cellular rejection, graft injury is due to direct cytotoxic activity of immune cells against graft parenchymal tissue. Antibody-mediated rejection, in contrast, is characterized by graft damage induced by circulating alloantibodies. Alloantibodies are produced by activated B-cells in response to antigen, costimulation, and cytokines such as interleukin (IL)-21 ([@B4], [@B5]).

Interleukin-21 was discovered by Parrish-Novak et al. using a functional cloning approach based on expression of the IL-21 receptor (IL-21R) gene and is located at chromosome 4 on position q26--q27 ([@B6]). The common γ-chain (γc) is a component of the IL-21R complex. IL-21 binding to the IL-21R/γc results in signaling *via* the JAK/STAT pathway ([@B6], [@B7]). This cytokine, a four-α-helix bundle, is a typical family I cytokine with broad pleiotropic actions and is primarily produced by T follicular helper cells (Tfh), Th17, and natural killer T-cells, rather than being generally produced by most tissue cells ([@B6], [@B8], [@B9]). IL-21 controls the activation, proliferation, differentiation, cytotoxicity, and survival of various target immune cells ([@B10], [@B11]). It is also important for the generation of B-cell responses in germinal centers resulting in isotype switching, affinity maturation, antibody production, and development of B-cells ([@B12], [@B13]). In particular, IL-21-mediated actions by Tfh cells are required for efficient antibody responses. The effectors and immune regulatory functions of IL-21 are mediated by binding to target B-cell surface receptors, which consist of α-chain and the γc that is shared with IL-2, IL-4, IL-7, IL-9, and IL-15 receptors ([@B10], [@B14], [@B15]).

Antibody-mediated ("humoral") rejection is a key cause of graft dysfunction and failure after organ transplantation ([@B1], [@B16], [@B17]) with 30--50% of failed allografts affected ([@B18]--[@B20]). Immunohistochemical and gene expression studies have shown that a large number of B-cells infiltrate the rejected allograft ([@B18], [@B21]--[@B24]), contributing to anti-donor responses.

Identifying the role of IL-21-mediated B-cell activation and differentiation pathways is critical for understanding the signaling pathways that underlie antibody-mediated rejection. In this review, we discuss the potential role of IL-21 on B-cells after organ transplantation.

IL-21 Signaling Pathway in B-Cells {#S2}
==================================

The IL-21R is expressed by human naive B-cells, memory B-cells, germinal center B-cells ([@B14]), and as shown recently, plasma cells ([@B25]). IL-21R is upregulated on human memory B-cells after activation by anti-CD40 mAb ([@B14]).

Binding of IL-21 with IL-21R/γc triggers the catalytic activation of JAK1 and JAK3. This causes phosphorylation of tyrosine residues on IL-21R/γc, providing docking sites for STAT proteins and other signaling molecules ([@B26]). On recruitment, STATs are phosphorylated and form homodimers or heterodimers, which translocate into the nucleus and modulate expression of the target genes ([@B27]), which regulate B-cells, such as B-cell-induced maturation protein-1 (Blimp-1) ([@B28]), B-cell lymphoma (BCL)-6 ([@B29]), activation-induced cytidine deaminase (AID) ([@B30]), granzyme ([@B31]), somatic hypermutation (SHM) ([@B32]), paired box 5 (Pax5) ([@B33]), X-box-binding protein 1 (XBP-1) ([@B34]), and Bim ([@B35]). IL-21 mediates B-cell proliferation, immunoglobulin (Ig) production, and apoptotic functions mainly through the potent effects of STAT3 and/or STAT1 activation but also, to a lesser extent, through STAT4 and STAT5 ([@B36]--[@B39]) (Figure [1](#F1){ref-type="fig"}).

![**IL-21 signaling pathway**. Many molecules participate in the IL-21 signaling pathway in B-cells, but the main molecules are IL-21R, JAK, and STAT to activate transcription of Blimp-1, BCL-6, AID, Pax5, SHM, granzyme B, XBP-1, and Bim. Generally, IL-21 binds with the IL-21R of B-cells to trigger signaling pathways. The JAK and STAT family molecules are activated in turn, while the balance of the transcription factors Blimp-1 and BCL-6 control the maturation B-cell.](fimmu-07-00319-g001){#F1}

B-Cell Activation and Differentiation {#S3}
=====================================

B-cell receptor (BCR) ligation triggers activation of multiple downstream molecules. Burton's tyrosine kinase (Btk), one of the downstream products of the BCR signaling pathway, selectively regulates IL-21-induced STAT1 phosphorylation and translocation in the nucleus. Btk deficiency is associated with arrested cell development at the pre-B-cell stage. In addition, Btk is involved in cytokine-controlled B cell activation. In concert with IL-21, CD40, and B-cell activating factor (BAFF), this kinase mediates the crosstalk with cytokine pathways through regulation of IL-21-induced phosphorylation of STAT1 ([@B25]). IL-21 and CD40L collaborate to synergistically promote Blimp-1 activation and plasma cell differentiation ([@B28]). CD40L alone has no direct effect on Blimp-1, but it greatly augments the IL-21-triggered JAK-STAT signaling. During this phase, STAT3 plays a more significant role than STAT1, because STAT3 mutations dramatically reduce the number of memory B-cells and abolish the ability of differentiation of naive B-cells into plasma cells ([@B10]). In contrast, STAT1 deficiency has no effect on memory B-cell formation *in vivo*. Thus, STAT3 is essential for the generation of effector memory B-cells from naive precursors ([@B40]). In addition, treatment with CD40L enhances the ability of STAT3 to upregulate Blimp-1 by removing BCL-6, which is a potent inhibitor of Blimp-1 expression. It has been speculated that IL-21 induces Blimp-1 and BCL-6 to regulate isotype-switched B-cells ([@B41]). Blimp-1 is a transcription factor and involved in plasma cell formation and maturation ([@B42]). Importantly, IL-21 costimulation upregulates expression of Blimp-1 ([@B43]). Consistent with this, IL-21-driven plasma cell differentiation from both naive blood B-cells and from memory B-cells are preceded by induction of Blimp-1 upregulation. Blimp-1 initiates plasma cell differentiation by downregulating MHC, CIITA, Pax5, and c-myc expression ([@B33], [@B44], [@B45]) and by inducing XBP-1 expression ([@B46], [@B47]). Blimp-1 level is very low when BCL-6 is over-expressed in B-cells ([@B48]). BCL-6 may block plasma cell differentiation due to downregulation of Blimp-1 ([@B49]). BCL-6 also can control B-cell development by BTB and RD2, two molecules that repress distinct functional effects of B-cells during the germinal centers reaction. BTB is required for B-cell survival and proliferation, while RD2 might be important for the prevention of terminal B-cell differentiation ([@B50]).

Since IL-21 activates STAT3 in B-cells, this may indicate that activation of STAT3 in human B-cells is pivotal for the induction of Blimp-1 expression and plasma cell differentiation ([@B11], [@B40]). It has been reported that IL-21-dependent CD86 upregulation is reliant on STAT3 phosphorylation and PI3K, revealing unexpected roles for these pathways in IL-21-mediated B-cell responses ([@B51]). In addition, IL-21 drives humoral immune responses *via* STAT3-dependent induction of the transcription factors required for plasma cell generation ([@B52]). These authors reported that IL-21*via* STAT3 sensitizes B-cells to the stimulatory effects of IL-2. Thus, IL-2 plays an adjunctive role in IL-21-induced B-cell differentiation. An absence of this secondary effect of IL-21 may amplify humoral immunodeficiency in patients with mutations in STAT3 and IL-21R due to impaired responsiveness to IL-21. In concert, IL-21 and BAFF stimulate and may maintain humoral immunity in humans ([@B53]). BAFF has the ability to substitute for CD40L activity with regards to IL-21 costimulation and differentiation of memory B-cells present in spleen ([@B53]) (Figure [2](#F2){ref-type="fig"}).

![**B-cell activation and differentiation**. Plasma cells are the main executors of B-cell regulation by the IL-21signal pathway. STAT3 is the dominant member of the STAT family in this respect. Transcription Blimp-1 has a positive role and BCL-6 a negative role in plasma cell maturation. Additionally, CD40L, ICOS, CD86, and BAFF can promote B-cell differentiation to plasma cells, while MHC, CIITA, Pax5, and c-myc are switched off during B-cell differentiation to plasma cells or memory B-cells, and XBP-1 is induced. The transcription factor BCL-6 activates BTB, which is required for cell survival and proliferation, while RD2 prevents terminal differentiation of B-cells.](fimmu-07-00319-g002){#F2}

Immunoglobulin Production {#S4}
=========================

Critical sites for the generation of antibody responses are the germinal centers in lymphoid follicles present in lymph nodes that also have been identified in transplanted organs ([@B4], [@B54]) where antigen-primed B-cells interact with T-cells, most of which are Tfh cells secreting IL-21. The B-cells are driven to undergo Ig isotype switching, with SHM and secretion of high affinity antibodies ([@B12], [@B55]--[@B58]). Bryant et al. reported that IL-21 stimulates naive B-cells to mainly produce IgM^+^ B-cells, while low frequencies of IgG and IgA secreted B-cells were also detected ([@B59]). When IgG was produced, IL-21 favors naive B-cells to develop into IgG1- and IgG3-secreting B-cells ([@B56], [@B57], [@B59]--[@B62]). It has been reported that IgM-specific Abs targeting BCR and IL-21 costimulation also induce the expression of AID ([@B63], [@B64]). Interestingly, although AID catalyzes both class switch recombination (CSR) and SHM, only CSR is induced in naive human B-cells after stimulation by IL-21 and anti-CD40 ([@B45], [@B47], [@B60], [@B65]). The C-terminal of AID is required for CSR but not for SHM ([@B65], [@B66]), and it has been postulated that IL-21 induces AID activity only at the C terminus. Multiple studies have shown that IL-21 causes CSR of CD40-stimulated human naive splenic IgM^+^ B-cells to IgG1 and IgG3, and CSR of CD40-stimulated cord blood B-cells to IgA ([@B47], [@B60]). As well as the molecules described above, among the group of cytokines called bone morphogenetic proteins (BMPs) ([@B67]), BMP-2, -4, -6, and -7 inhibit CD40L/IL-21-induced production of IgM, IgG, and IgA. In memory B-cells, BMP-6 upregulated expression of DNA-binding protein inhibitor genes, but potently inhibited CD40L/IL-21-induced upregulation of the transcription factor XBP-1 ([@B34]). This factor is crucial for final stage in plasma cell differentiation ([@B34]). As described above, Btk is an efficient propagator of IL-21 signaling, critical for CSR in human B-cells and secretion of Ig ([@B25]). Additionally, the outcome of IL-21-mediated Ig secretion depends on the presence of IL-4 and IL-10, which influence the outcome of IL-21-mediated CSR. IL-10 acts synergistically with IL-21 to induce secretion of IgA by CD40L-stimulated human B-cells, whereas IL-4 has an inhibitory effect ([@B47]). As shown by the group of Bromberg, IL-10 deficiency in B-cells prevents transplantation tolerance, resulting in decreased follicular immune regulatory CD4^+^ T-cells, a recently identified T cell subset, and increased IL-21 expression by Tfh cells in the B-cell and T-cell marginal zones ([@B68]). This has implications for our understanding of the mechanisms involved in tolerance and show at the same time that B cells play pivotal roles in the induction of this immune phenomenon ([@B68]). Interestingly, as with IL-21, IL-10, in combination with toll-like receptor (TLR), signaling also enhances phosphorylation of STAT3, resulting in increased IgG production. Hence, IL-21 and IL-10 increase the activity of the TLR--MyD88--STAT3 pathway in human B-cells by enhancing Ig production stimulated by STAT3 phosphorylation ([@B69]) (Figure [3](#F3){ref-type="fig"}).

![**Immunoglobulin (Ig) production**. Ig is produced by plasma cells, so the signaling pathway for mediation of Ig production is similar to that for IL-21-mediated plasma cell maturation. Some molecules, however, have a specific role in Ig production: BMP-2, -4, -6, and -7 may exert a negative influence and Btk a positive influence. In addition, some cytokines contribute to Ig CSR. IL-4 can induce to IgG1 formation, IFN-γ to IgG2a, and IL-10 to IgA.](fimmu-07-00319-g003){#F3}

Regulatory B (B10) Cells {#S5}
========================

Interleukin-21 may also modulate the immune response by immune-dampening regulatory mechanisms. One of these is performed by B10 cells, named for their ability to produce abundant IL-10 ([@B70]). Expression of IL-10 is a common characteristic of regulatory immune cells, and B10 cells are thus referred to as regulatory B-cells ([@B71], [@B72]). The B10 cell subset represents \<1% of peripheral blood B-cells in humans ([@B73]). A high proportion of peripheral B10 cells and progenitor (pro)-B10 are present in the CD24^hi^CD27^+^ B-cell subset, and approximately 60% also express CD38 ([@B73]). B10 progenitors and B10 cells have been identified in human ([@B73]). *Ex vivo*, human B10 progenitors can be driven to develop into B10 cells by lipopolysaccharide (LPS) or 5′-C-phosphate-G-3′ (CpG), or by CD40 ligation. *In vitro*, IL-21/CD40-receptor signaling pathways can promote the development and expansion of B10 cells by four million-fold to suppress the immune response. IL-21R signaling, together with major histocompatibility complex class II and CD40 cognate, interacts with CD4^+^ T-cells and although not required for B10 cell development, are necessary for B10 cell effector functions that result in antigen-specific responses. Interestingly, BCR ligation augments human B-cell IL-10 responses to CpG ([@B74]). Whether human B10 cells develop into antibody-secreting cells, or enter the memory B10 cell subset, remains to be determined ([@B75]). B10 cells may represent a subset, which is similar to regulatory T-cells ([@B76]) (Figure [4](#F4){ref-type="fig"}).

![**Regulatory B (B10) cells**. IL-21 binding to IL-21R expressed on B10 pro-cells may trigger B10 pro-cell maturation to B10 cells. Synergistically with MHC-II, LPS, CpG, or CD40 ligation stimulation can induce this cell subset to produce IL-10.](fimmu-07-00319-g004){#F4}

B10 cells are able to control the immune response, but an excessive reaction from these cells may also promote tumor cell growth or chronic infection ([@B77]). It is possible that regulatory fine tuning by B-cells and IL-21 production by T-cells might be a key factor in maintaining immune tolerance ([@B78]). Most investigations of B10 cells have concentrated on autoimmune diseases ([@B79]), but a few have assessed their role in transplantation ([@B80]). A mouse islet T-cell transplantation study has demonstrated that B10 cells control immune responses ([@B81]).

B-Cell Apoptosis Mediated by IL-21 {#S6}
==================================

The effects of IL-21 on B cells depend on the costimulatory signals that are received. In the absence of signal from a T cell (such as the T cell engaging CD40), BCR activation is required for IL-21-mediated B cell apoptosis ([@B15], [@B29], [@B35]). The balance between STAT1 and STAT3 is critical for IL-21-induced B-cell apoptosis in the IL-21 signaling pathway. STAT1 mainly acts in cell cycle arrest and apoptotic cell death ([@B45], [@B47], [@B82], [@B83]). By contrast, STAT3 mostly exerts an anti-apoptotic effect, especially in numerous malignancies where it is constitutively active ([@B83]). In some circumstances, IL-21 can induce apoptosis of B-cells activated *via* signals through the TLR, LPS, CpG, anti-IgM, and IL-4 ([@B11], [@B15]). Complete protection from IL-21-mediated apoptosis was not inhibited by other molecules involved in apoptotic pathways. Functional studies have demonstrated that IL-21 substantially inhibited proliferation and Bim-dependent apoptosis of activated mouse B-cells ([@B47]). Hagn et al. reported that CpG together with IL-21 may enhance their apoptosis-inducing and immunogenizing effects ([@B84]). It is therefore possible that combining CpG with IL-21 could more effectively induce apoptosis in B-cells than CpG or IL-21 alone. Furthermore, IL-21 can inhibit B-cell proliferation when receiving a strong signal *via* TLR while preventing apoptosis of B-cells *via* upregulation of B-cell leukemia/lymphoma-X linked (BCL-XL), an anti-apoptotic protein of the BCL-2 homology 3 (BH3) family ([@B11], [@B85]) (Figure [5](#F5){ref-type="fig"}). From this viewpoint, IL-21 appears to act as an immunosuppressive cytokine on B-cells. This finding indicates that the apoptotic effects of IL-21 may only be relevant in situations where a humoral immune response is improperly triggered, thereby shutting down at least one arm of the immune system before extensive damage is done ([@B7]).

![**B-cell apoptosis**. IL-21 can also induce apoptosis of B-cells when activated by LPS, TLRs, CpG, anti-IgM, or IL-4 in the absence of T-cell signals. In the absence of such molecules, the balance between STAT1 and STAT3 regulates B-cell apoptosis *via* the IL-21 signaling pathway. STAT1 induces cell death, while, conversely, STAT3 exerts an anti-apoptotic effect. Bim also plays an apoptotic role and BCL-XL an anti-apoptotic role.](fimmu-07-00319-g005){#F5}

Granzyme B Production by B-Cells {#S7}
================================

Interleukin-21 can induce BCR-stimulated human B-cells to differentiate into granzyme B-expressing cytotoxic cells (GrB) in a STAT3-dependent manner in the absence of a CD40 signal ([@B31], [@B77], [@B86]--[@B88]). GrB^+^ B-cell numbers are dependent on IL-21 production, and increasing doses of anti-IL-21 decreased the number of GrB-expressing B-cells in co-culture systems ([@B78]). The increase in GrB^+^ B-cells in the circulation of tolerant recipients may be due to a direct effect of IL-21 ([@B78]). GrB secreted by B cells may play a key role in the regulation of immune responses ([@B78], [@B89]). Xu et al. showed that IL-21 initially triggers transcription of the GrB gene in B-cells, while STAT3 is required for GrB synthesis in PCs activated by IL-21 and IL-15. The defect in GrB formation in STAT3-deficient B-cells might arise from a lack of cell proliferation and differentiation ([@B88]). Recent *in vitro* studies have indicated that CD40 signaling in B-cells inhibits their differentiation into GrB^+^ cells ([@B31], [@B77]) (Figure [6](#F6){ref-type="fig"}).

![**Granzyme B expression by B-cells**. IL-21 can induce BCR-stimulated B-cells to differentiate into granzyme B (GrB), an effect which is dependent on STAT3 and which is promoted by IL-15 or CpG. CD40 inhibits differentiation into GrB-cells.](fimmu-07-00319-g006){#F6}

IL-21 as a Possible Player in Alloreactivity after Transplantation {#S8}
==================================================================

Antibody-mediated rejection is a major problem after organ transplantation mediated by anti-HLA antibodies and donor-specific antibodies (DSA). This poorly defined alloimmune response is refractory to treatment with conventional immunosuppression ([@B1]). From our recent studies, we know that in this process, B-cells can be activated by IL-21-producing Tfh cells and differentiate into Ig-producing plasma cells. We reported that these Tfh cells as well as B-cells infiltrate the allograft during rejection and colocalize in follicular-like structures in the transplanted kidney ([@B4], [@B18]). These tide clusters of T and B-cells form highly organized lymphoid structures named tertiary lymphoid organs (TLOs). Associations between the presence of these TLO and poor graft outcome have been reported ([@B90]--[@B92]). In contrast, Xu et al. reported that IL-17, and not IL-21, is responsible for lymphoid neogenesis. Therefore, they suggested that Th17, but not Tfh, cells could play a role in the process of lymphoid neogenesis ([@B93]). It is likely that infiltrated and organized T and B-cells contribute to the anti-donor response by antigen presentation of B cells and by help of Tfh cells to the infiltrated B-cells. Besides IL-21, the capacity of Tfh cells to provide help to B-cells depends upon the acquisition of molecules that are known to play functional roles in T-cell--B-cell interactions, such as CD40 ligand, inducible co-stimulator (ICOS), and programed death 1 (PD-1) ([@B18], [@B33], [@B94], [@B95]).

In organ transplantation, specifically targeting B-cells to decrease plasma cell differentiation by either IL-21-dependent B cell apoptosis or IL-21R blockade may provide novel approaches for the prevention of the development of *de novo* DSA and treatment of antibody-mediated rejection.

The first approach is speculative and based on the finding that IL-21 induces B-cell apoptosis when costimulation signals are absent ([@B15], [@B29], [@B35]). At the same time, IL-21 might stimulate the cytolytic functions of alloantigen activated CD8 T cells, the aggressors in acute rejection ([@B96], [@B97]). Therefore, we should be careful with IL-21 cytokine treatment. This strategy should first be tested in experimental animal models by using various concentrations of IL-21 to define if B cell apoptosis and T cell cytotoxicity rely on the same or different concentrations of IL-21. This knowledge is helpful to better understand the role of IL-21 in B-cell-mediated immune processes such as apoptotic cell death.

The second approach could be blockade of the IL-21 pathway proven to affect the production of pathogenic immunoglobulins in animal models of autoimmune diseases. In these studies, blockade of the IL-21R signaling pathway reduced B-cell-mediated diseases ([@B98]). Also, in a mouse model of islet transplantation, mIL-21R-Fc combined with CTLA-4-Ig diminished T-cell and B-cell effector functions, and tolerance was induced in a subgroup of treated animals ([@B99]). It is critical to determine whether neutralizing the IL-21 function also inhibits production of anti-HLA antibodies and DSA in organ transplant recipients. So far, such studies have not been conducted, but based on the biological functions of IL-21, the promising findings in animal models for autoimmune diseases and *in vitro* studies, targeting the IL-21 pathway could be expected to reduce the incidence of antibody-mediated alloreactivity. Our studies using peripheral T-cells and B-cells derived from kidney transplant patients showed that the interaction between IL-21-producing Tfh cells and B-cells could be inhibited by an IL-21 receptor antagonist. In these co-cultures, B-cell differentiation and IgM and IgG production were diminished ([@B4]). We believe that IL-21-producing Tfh cells play a dominant role in alloreactivity and should be targeted by novel immunosuppressive agents.

Like many other cytokines, IL-21 has multiple functions. In addition to its actions in B-cell apoptosis and differentiation it also drives regulatory B10 responses. These cells have been shown to suppress T-cell-mediated rejection induced by mismatched MHC molecules and prolong allogeneic islet T-cell survival, suggesting a potential regulatory role for B10 cells in organ transplantation ([@B80], [@B81]). Since IL-21 can promote regulatory B10 cell proliferation, harnessing the anti-inflammatory properties of B10 cells by anti-IL-21 agents could potentially stimulate antibody-mediated rejection and promote a less favorable tolerogeneic environment by modulating the plasma cell/Breg (B10) balance ([@B68]) (Figure [7](#F7){ref-type="fig"}). Recently, another type of Bregs was described, which could be inhibited by anti-IL-21 treatment. The number of GrB-producing B-cells with regulatory properties was significantly higher in tolerant patients compared to patients with stable graft function ([@B78]). This observation suggests that targeting the IL-21R pathway with immunosuppressive agents may harness this cell population. Data in this area, however, remain sparse.

![**Overview of the immunostimulatory and immunoregulatory effects of IL-21**. IL-21 promotes B-cell proliferation, plasma cell differentiation, B-cell memory, and Ig class switching, and is also important for the development of IL-10 + regulatory B-cells (Bregs/B10), B-cell apoptosis, and granzyme B producing cells.](fimmu-07-00319-g007){#F7}

Conclusion {#S9}
==========

In general, IL-21 promotes humoral immunity, and IL-21 blockade may attenuate B-cell hyperactivity in which also costimulatory signals are involved. However, B-cells may have a dual effect, acting both as a driver and as a regulator of the immune system ([@B78], [@B79], [@B100]). In B-cells that recognize Ag and receive T-cell help, IL-21 induces survival, proliferation, isotype switching, and differentiation to Ig-secreting plasma cells or GrB-producing B-cells. B-cells can also cause cell death or, in the form of regulatory B10 cells, can induce autoimmunity if they receive a strong signal *via* BCR, or *via* TLR, and IL-21 costimulation. An equilibrium between effector and suppresser cells is necessary to maintain B-cell homeostasis and the immune balance, especially for the prevention of antibody-mediated transplantation rejection. Future studies should focus on elucidating details of the signaling cascades and downstream changes in gene and protein expression within B-cells in response to IL-21, either alone or in combination with other molecules. This knowledge may ultimately lead to an effective therapeutic strategy to overcome antibody-mediated rejection following transplantation, particularly by targeting the differentiation of B-cells into plasma cells *via* IL-21 signaling pathways.
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